secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000950170-25-102065
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight appoints former Axonics CEO Raymond Cohen to board of directors
-----------------------------------------------------------------------

- Raymond W. Cohen, former CEO of Axonics (sold to BSX for $3.7B), appointed to RxSight board as Class I director effective July 31, 2025.
- Cohen also led SoniVie sale to Boston Scientific for $600M; has over 40 years medtech experience.
- Will serve until 2028 annual meeting; receives standard non-employee director compensation including $277,500 initial RSU grant.
- Press release issued August 4, 2025; no other changes to board or management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025102065/0000950170-25-102065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025102065/rxst-20250731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer